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Background:  This  postlicensure  study  was conducted  to assess  immunogenicity  and  safety  of PCV7  catch-
up regimens  in  previously  unvaccinated  older  infants  and  young  children  in China.
Methods:  Healthy  children  121  days  to <72  months  were  grouped  by age  and  immunized  with 1 of 4
PCV7  dosing  regimens.  Serotype-speciﬁc  IgG geometric  mean  concentrations  (GMCs)  and  percentage  of
subjects with  IgG  ≥  0.35  g/mL  were  assessed  before  vaccination  and  1 and  12  months  postvaccination.
The  incidence  of  clinically  important  adverse  events  (AEs)  and  serious  AEs  (SAEs),  AEs leading  to  study
withdrawal,  and  protocol-related  AEs  were  assessed  throughout  the  study.
Results: Prevaccination  serotype-speciﬁc  GMCs  were  generally  low  in  subjects  <24  months;  the  major-
ity of  children  24 to <72  months  had  IgG concentrations  ≥0.35  g/mL.  One  month  postvaccination,
GMCs  were  similar  across  groups  for the  7 PCV  serotypes,  ranging  from  3.95  to 13.02  g/mL;  the high-
est  antibody  levels  were  observed  for serotype  14. Regardless  of dosing  regimen,  >90%  of  subjects  had
IgG  ≥ 0.35  g/mL for each  PCV  serotype.  At 12-month  follow-up,  IgG  GMCs  ranged  from  0.65  to 5.19,
and  all  remained  above  prevaccination  IgG GMC;  >70% of  subjects  had  IgG  ≥  0.35  g/mL.  Older  children
generally  had the  most  robust  immune  response  both  at 1  month  postvaccination  and during  12-month
follow-up.  PCV7  was  well  tolerated.  Pyrexia,  which  was  mild  to  moderate  in severity, was  the  most
common  AE.  Two  subjects  reported  SAEs  (n =  4),  and  there  was  1 study  withdrawal;  none  of  these  were
considered  treatment  related.
Conclusion:  In  China,  PCV7  catch-up  vaccinations  given  to older  infants  and  young  children  naive  to
pneumococcal  vaccines  resulted  in a robust  immune  response  to all serotypes;  this  response  persisted
after  1 year.  PCV7  was  well  tolerated  in  Chinese  infants  and  children.
ublis© 2015  The  Authors.  P
. IntroductionStreptococcus pneumoniae is a leading cause of pneumonia and
nvasive bacterial disease, including meningitis, in young children
Abbreviations: GMC, geometric mean concentration; GMFR, geometric mean
old rise; IPD, invasive pneumococcal disease; PCV7, 7-valent pneumococcal conju-
ate vaccine.
∗ Corresponding author. Tel.: +1 484 865 2010.
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/).hed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
worldwide [1]. It is estimated that 1.6 million people worldwide
die of pneumococcal disease every year, including up to 1 million
children younger than 5 years of age [1]. In 2012, China accounted
for 4% of worldwide deaths in children younger than 5 years, despite
a 74% decrease in the mortality rate in this age group since 1990
[2]. Sixteen percent of those childhood deaths in China were caused
by pneumonia, which is the second leading cause of death after
neonatal causes [2]. Pneumococcal disease remains a signiﬁcant
cause of morbidity and mortality among children in China [3].
Previous prelicensure and postlicensure studies have demon-
strated the effect of a 7-valent pneumococcal conjugate vaccine
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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PCV7) targeting serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in
reventing pneumococcal disease [4–9]. The most prevalent pneu-
ococcal serotypes among 218 invasive pneumococcal disease
trains from 12 hospitals across China, collected from 2005 to
011, were 19A (22%), 19F (22%), 14 (8%), 3 (7%), and 23F (5%),
hich accounted for 64% of all strains; the estimated coverage by
CV7 was 41% [10]. Similarly, the most prevalent pneumococcal
erotypes among 471 invasive pneumococcal disease strains from
3 hospitals across China, collected from 2010 to 2011, were 19F
24%), 19A (13%), 3 (10%), 14 (9%), 23F (6%), 15 (5%) and 6A (5%);
he estimated coverage by PCV7 was 45% overall, 59% in children,
nd 42% in adults [11].
In clinical trials enrolling Chinese infants, PCV7 has been shown
o be safe and immunogenic when given either separately or
oncomitantly with a diphtheria, tetanus, and acellular pertussis
accine at 3, 4, and 5 months of age [9]. Health outcomes stud-
es support the use of PCV7 administered as primary and booster
mmunizations to reduce morbidity and mortality related to pneu-
ococcal disease in Chinese children [12].
In infants, PCV7 is administered in a 4-dose schedule, typically
t 3, 4, 5, and 12 to 15 months of age. Based on global data, PCV7 was
lso approved for catch-up vaccination in previously unvaccinated
lder children aged 7 months to 5 years. This postlicensure study
as conducted to assess immunogenicity and safety of PCV7 catch-
p vaccinations in previously unvaccinated older infants and young
hildren.
. Methods
.1. Study subjects and design
This phase 4, open-label, single-center study conducted from
ovember 2010 to March 2012 in China enrolled healthy Chi-
ese infants and children aged 121 days to <72 months. Informed
onsent was supplied by a parent or guardian. Key exclusion
riteria included previous use or adverse reaction to any pneumo-
occal vaccine, culture-conﬁrmed invasive pneumococcal disease,
mmunodeﬁciency, receipt of blood products within 12 weeks of
osing, or any signiﬁcant neurologic, psychiatric, or medical con-
ition.
Subjects were stratiﬁed into 4 groups based on age: subjects
21 to <212 days of age received 4 doses of PCV7 (3 doses + toddler
ose); subjects 212 days to <12 months of age received 3 doses of
CV7 (2 doses + toddler dose); subjects 12 to <24 months of age
eceived 2 doses of PCV7; and subjects 24 to <72 months of age
eceived 1 dose of PCV7 (Fig. 1).
This study complied with the International Ethical Guide-
ines for Biomedical Research Involving Human Subjects [13], the
Fig. 1. Immunization schedule. PCV7 = 7-valent pneumococcal conjugate vaccine.015) 3580–3585 3581
Declaration of Helsinki [14], and International Conference on Har-
monisation Guidelines for Good Clinical Practice [15].
2.2. Study vaccine and administration
PCV7 (Prevnar 7/Prevenar 7®, Wyeth Vaccines, New York) con-
tained polysaccharide from pneumococcal serotypes 4, 6B, 9V, 14,
18C, 19F, and 23F (batch numbers: E61516E52444 [expiration date:
March 2013] and E19166D94429 [expiration date: April 2012])
individually conjugated to a nontoxic diphtheria toxin mutant
(cross-reactive material 197). Each 0.5-mL single-dose syringe con-
tained 2 g of each pneumococcal serotype, except type 6B, which
was included at 4 g. The ﬁnal formulation contained 0.125 mg
aluminum as aluminum phosphate per 0.5-mL dose. The vaccine
was preservative-free and stored at 2 ◦C to 8 ◦C. A single dose of
PCV7 was administered intramuscularly into the deltoid muscle
of the arm or anterolateral muscle of the thigh according to the
immunization schedule.
2.3. Immunogenicity evaluations
The primary immunogenicity objectives were to assess
serotype-speciﬁc immune responses 1 month after the last dose
of PCV7 and prevaccination antibody levels to the 7 pneumococcal
serotypes in PCV7 in each age group. Secondary immunogenicity
objectives were to assess serotype-speciﬁc immune responses 1
month after the third dose of PCV7 in subjects aged 121 to <212
days, the second dose in subjects aged 212 days to <12 months,
and the ﬁrst dose in subjects aged 12 to <24 months, and antibody
levels 12 months after the last PCV7 dose in all age groups.
Blood samples were collected for all subjects before the ﬁrst
vaccination and approximately 1 month after the third dose of
PCV7 for subjects aged 121 to <212 days, 1 month after the sec-
ond dose of PCV7 for subjects aged 212 days to <12 months, and
1 month after the ﬁrst dose of PCV7 for subjects aged 12 to <24
months. Another blood sample was taken approximately 1 and 12
months after the last dose of PCV7. For each blood sample, serum
concentrations of anticapsular immunoglobulin G (IgG) were mea-
sured by enzyme-linked immunosorbent assay (ELISA) for the 7
pneumococcal serotypes in PCV7.
2.4. Safety evaluations
The safety objectives were to assess the incidence of clinically
important related adverse events (AEs) and serious AEs (SAEs), AEs
leading to study withdrawal, and protocol-related AEs; these were
collected from all subjects receiving at least 1 dose of PCV7. AEs
were graded as mild, moderate, or severe and assessed for associa-
tion with the study vaccine. All AEs were collected from the signing
of the informed consent form through the end of the study, which
was approximately 12 months after the last dose of PCV7.
2.5. Statistical analysis
2.5.1. Sample size calculations
Approximately 80 subjects aged 121 to <212 days and 212 days
to <12 months, 100 subjects aged 12 to <24 months, and 144 sub-
jects aged 24 to <72 months were considered sufﬁcient to provide
estimates of the serotype-speciﬁc IgG geometric mean concen-
tration (GMC) within 25% precision and responder rates with 5%
precision in each group separately using 95% CIs. Assuming a 20%
dropout rate, 505 subjects (100 subjects each aged 121 to <212
days and 212 days to <12 months, 125 subjects aged 12 to <24
months, and 180 subjects aged 24 to <72 months) would ensure
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Table 1
Subject demographics.
Age group
121–<212 d (n = 88) 212 d–<12 mo  (n = 87) 12–<24 mo (n = 115) 24–<72 mo (n = 177) Total (n = 467)
Gender
Female, n (%) 50 (56.8) 43 (49.4) 58 (50.4) 93 (52.5) 244 (52.2)
Male, n (%) 38 (43.2) 44 (50.6) 57 (49.6) 84 (47.5) 223 (47.8)
Race
Asian, n (%) 88 (100) 87 (100) 115 (100) 177 (100) 467 (100)
Mean (SD) age (mo)
At dose 1 5.3 (0.9) 9.8 (1.4) 17.5 (4.2) 44.5 (13.0) 24.0 (18.5)
At  dose 2 6.4 (0.9) 10.8 (1.5) 19.6 (4.1) – 13.0 (6.3)
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ashes indicate that no vaccine was administered.
he required number of evaluable subjects for immunogenicity and
afety analysis.
.5.2. Immunogenicity evaluations
The evaluable immunogenicity population consisted of eligible
ubjects who received all assigned vaccinations, had blood drawn
ithin the required time frames, had at least 1 valid and deter-
inate assay result for the proposed analysis, had received no
rohibited vaccines, and had no other major protocol violations.
erotype-speciﬁc pneumococcal IgG GMCs and the proportion of
ubjects achieving an IgG ≥ 0.35 g/mL were computed for each
lood sample. For each serotype, exact, unconditional 2-sided 95%
Is were calculated. Geometric mean fold rises (GMFRs) were sum-
arized by GMCs, and CIs were computed using logarithmically
ransformed assay results. Only subjects with both prevaccination
nd postvaccination results were included in the GMFR analysis.
.5.3. Safety evaluations
All subjects who received at least 1 dose of PCV7 were included
n the safety population. All safety analyses were completed for
ach age group separately; no comparisons were made among
roups. AEs were summarized using descriptive statistics.
. Results
.1. Subjects
This study enrolled 506 subjects; 505 (99.8%) received at least
 dose of vaccine, and 467 (92.3%) were included in the evaluable
mmunogenicity population. Across age groups, the percentage of
ubjects receiving all planned doses was 90.0% in subjects aged
21 to <212 days (4 doses), 88.1% in subjects aged 212 days to <12
onths (3 doses), 94.4% in subjects aged 12 to <24 months (2 doses),
nd 100.0% in subjects aged 24 to <72 months (1 dose). In total, 467
92.3%) subjects were assessed 1 month after the last vaccination,
nd 433 (85.6%) subjects were included in the 12-month follow-up
nalysis.
The evaluable immunogenicity population included 223 (47.8%)
ale and 244 (52.2%) female subjects, all of whom were Asian.
ender distribution was similar across groups, with slightly more
emale subjects than male subjects in the youngest and oldest age
roups. The mean age at dose 1 was 5.3, 9.8, 17.5, and 44.5 months
or subjects from the youngest to oldest age groups, respectively
Table 1)..2. Immunogenicity evaluations
For all 7 serotypes, prevaccination GMCs were similar in all
ubjects aged <24 months and generally higher in subjects in the– – 7.4 (0.9)
– – 14.0 (1.4)
oldest age group; however, IgG GMCs for serotype 14 in sub-
jects in the youngest age group (121 to <212 days) was  notably
higher than in subjects aged 212 days to <24 months (Table 2).
Serotype-speciﬁc IgG GMCs 1 month after the last vaccine dose
were generally similar across age groups for the 7 PCV serotypes,
with highest levels observed for serotype 14. GMCs ranged from
3.95 to 13.02 g/mL for subjects in the 2 youngest age groups and
from 4.03 to 11.98 g/mL for the 2 oldest age groups (Table 2).
GMFRs for all age groups, calculated after the infant series in sub-
jects aged 121 to <212 days and 212 days to <12 months and after
the last vaccination in subjects aged 12 to <24 months and 24 to
<72 months, had a 95% CI with a lower limit >1, indicating that
postvaccination IgGs were higher than prevaccination IgG. The low-
est response was  generated against serotype 6B and the greatest
against serotype 4 (Table 3).
Before vaccination, the proportion of subjects with an
IgG ≥ 0.35 g/mL for the 7 PCV serotypes ranged from 0% to 29.5%,
0% to 28.1%, 2.6% to 49.0%, and 11.0% to 85.9% for subjects in the
youngest to oldest age groups, respectively. In fact, >70% of sub-
jects aged 24 to <72 months had an IgG ≥ 0.35 g/mL for 4 of the 7
serotypes (6B, 9V, 19F, and 23F) before vaccination (Table 4). One
month after the last dose of study vaccine, the percentage of sub-
jects with an IgG ≥ 0.35 g/mL for all 7 serotypes was >90% in the 2
youngest age groups and >95% in the 2 oldest age groups (Table 4).
For subjects receiving more than 1 vaccination, IgG GMCs were
determined 1 month after the second-to-last dose. GMCs 1 month
after the third dose of PCV7 for subjects 121 to <212 days, the sec-
ond dose for subjects 212 days to <12 months, and the ﬁrst dose for
subjects 12 to <24 months ranged from 2.45 to 11.16, 2.66 to 8.46,
and 1.92 to 8.44 g/mL, respectively. In all subjects, postvaccination
GMCs were statistically signiﬁcantly higher than prevaccination
levels.
Twelve months after the last dose of PCV7, IgG GMCs for the
7 PCV serotypes were similar across subjects in the 3 youngest
age groups and were generally higher in subjects in the oldest age
group. GMCs ranged from 0.78 to 3.22, 0.65 to 2.31, 0.96 to 2.61, and
1.27 to 5.19 g/mL for subjects in the youngest to oldest age groups,
respectively, and remained above prevaccination levels (Table 2).
One year postvaccination, >70% of subjects had IgG ≥ 0.35 g/mL
(data not shown).
3.3. Safety
Overall, a total of 13 AEs were reported in 12 subjects. AEs were
reported for 4 subjects each in the 121 to <212 days and 212 days
to <12 months age groups, 3 subjects aged 12 to <24 months, and
1 subject aged 24 to <72 months. One event was reported for each
subject, except for 1 subject aged 12 to <24 months, for whom 2
events were reported. The most common AE was pyrexia (9 events
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Table 2
Pneumococcal IgG GMCs (g/mL) prevaccination, 1 month, and 1 year after last PCV7 vaccination.
Serotype Age group
121–<212 d 212 d–<12 mo 12–<24 mo 24–<72 mo
n = 80–88 n = 64–87 n = 100–115 n = 156–177
GMC (95% CIa) GMC (95% CIa) GMC (95% CIa) GMC (95% CIa)
Pre 1 Month 1 Year Pre 1 Month 1 Year Pre 1  Month 1 Year Pre 1 Month 1 Year
4 0.01b (0.01, 0.02) 6.90 (5.61, 8.48) 0.78 (0.62, 0.98) 0.01 (0.01, 0.02) 7.16 (6.09, 8.42) 0.65 (0.52, 0.82) 0.02 (0.01, 0.02) 7.53 (6.70, 8.46) 0.96 (0.80, 1.14) 0.06 (0.05, 0.08) 9.45 (8.38, 10.65) 1.27 (1.11, 1.45)
6B  0.12 (0.10, 0.15) 8.01 (6.24,10.30) 3.22 (2.41, 4.29) 0.16 (0.12, 0.22) 5.79 (4.64, 7.23) 2.31 (1.77, 3.03) 0.27 (0.21, 0.35) 4.81 (3.89, 5.96) 2.38 (1.89, 3.00) 1.30 (1.08, 1.55) 6.36 (5.32, 7.59) 4.20 (3.49, 5.04)
9V  0.10 (0.08, 0.12) 4.11 (3.40, 4.96) 1.26 (1.00, 1.59) 0.10 (0.08, 0.13) 4.64 (3.93, 5.47) 0.98 (0.79, 1.21) 0.17 (0.13, 0.21) 4.67 (4.18, 5.21) 1.44 (1.20, 1.71) 0.66 (0.56, 0.77) 6.14 (5.42, 6.95) 2.23 (1.94, 2.56)
14  0.16 (0.12, 0.22) 12.75 (10.32, 15.76) 1.84 (1.40, 2.41) 0.04 (0.03, 0.05) 13.02 (10.89, 15.57) 2.18 (1.62, 2.94) 0.03b (0.02, 0.04) 11.98 (10.51, 13.65) 2.61 (2.09, 3.27) 0.36 (0.26, 0.50) 9.86 (8.03, 12.10) 5.19 (4.25, 6.33)
18C  0.04 (0.03, 0.06) 4.65 (3.81, 5.69) 0.87 (0.69, 1.10) 0.02 (0.01, 0.02) 4.65 (3.86, 5.61) 0.71 (0.59, 0.85) 0.02 (0.02, 0.03) 5.40 (4.78, 6.10) 0.98 (0.84, 1.15) 0.12 (0.10, 0.16) 7.39 (6.41, 8.51) 1.46 (1.24, 1.72)
19F  0.11 (0.09, 0.14) 4.05 (3.07, 5.36) 1.25 (0.95, 1.64) 0.09 (0.07, 0.12) 4.02 (3.05, 5.31) 1.29 (0.85, 1.95) 0.13 (0.10, 0.17) 4.03 (3.26, 4.98) 1.39 (1.03, 1.88) 0.71 (0.57, 0.89) 4.53 (3.73, 5.49) 2.85 (2.28, 3.56)
23F  0.07 (0.06, 0.09) 4.75 (3.77, 5.99) 1.38 (1.07, 1.77) 0.08 (0.06, 0.11) 3.95 (3.19, 4.89) 1.20 (0.91, 1.59) 0.17 (0.12, 0.23) 4.18 (3.51, 4.96) 1.79 (1.45, 2.21) 0.88 (0.74, 1.04) 5.64 (4.84, 6.57) 2.49 (2.13, 2.92)
GMC  = geometric mean concentration; IgG = immunoglobulin G; PCV7 = 7-valent pneumococcal conjugate vaccine; Pre = prevaccination.
a CIs are back-transformations of conﬁdence levels based on the Student t distribution for the mean logarithm of the concentrations.
b Values are below the lower limit of quantitation for the assay.
Table 3
Prevaccination pneumococcal IgG GMCs (g/mL) and GMFRs 1 month after the last PCV7 vaccination.
Serotype Age group
121–<212 d 212 d–<12 mo 12–<24 mo 24–<72 mo
n = 85–88 n = 63–87 n = 99–115 n = 99–115
Pre 1 Month Pre 1 Month Pre 1 Month Pre 1 Month
GMC  (95% CIa) GMFRb (95% CIa) GMC (95% CIa) GMFRb (95% CIa) GMC (95% CIa) GMFRc (95% CIa) GMC  (95% CIa) GMFRc (95% CIa)
4 0.01 (0.01, 0.02) 453.17 (344.56, 596.01) 0.01 (0.01, 0.02) 705.95 (540.50, 922.05) 0.02 (0.01, 0.02) 425.21 (330.20 547.56) 0.06 (0.05, 0.08) 147.54 (119.12, 182.73)
6B  0.13 (0.10, 0.15) 23.10 (18.15, 29.40) 0.16 (0.12, 0.23) 16.64 (11.17, 24.79) 0.27 (0.21, 0.35) 17.00 (12.64, 22.87) 1.30 (1.08, 1.55) 4.90 (4.17, 5.77)
9V  0.10 (0.08, 0.12) 43.38 (33.42, 56.32) 0.10 (0.08, 0.13) 44.72 (34.22, 58.44) 0.17 (0.13, 0.21) 27.53 (22.00, 34.44) 0.66 (0.56, 0.77) 9.33 (8.02, 10.86)
14  0.16 (0.12, 0.22) 69.90 (45.95, 106.35) 0.04 (0.03, 0.05) 217.21 (152.52, 309.33) 0.03 (0.02, 0.04) 384.28 (283.22, 521.41) 0.36 (0.26, 0.50) 27.38 (20.93, 35.82)
18C  0.04 (0.03, 0.06) 106.74 (76.83, 148.31) 0.02 (0.01, 0.02) 317.90 (219.65, 460.10) 0.02 (0.02, 0.03) 222.79 (175.92, 282.14) 0.12 (0.10, 0.16) 59.55 (48.56, 73.03)
19F  0.11 (0.09, 0.14) 32.52 (23.39, 45.21) 0.09 (0.07, 0.12) 33.66 (24.28, 46.65) 0.13 (0.10, 0.17) 31.54 (22.90, 43.44) 0.71 (0.57, 0.89) 6.45 (5.13, 8.09)
23F  0.07 (0.06, 0.09) 34.01 (24.98, 46.32) 0.08 (0.06, 0.11) 30.77 (21.30, 44.45) 0.17 (0.12, 0.23) 25.31 (18.98, 33.75) 0.88 (0.74, 1.04) 6.45 (5.42, 7.68)
GMC  = geometric mean concentration; GMFR = geometric mean fold rise; IgG = immunoglobulin G; PCV7 = 7-valent pneumococcal conjugate vaccine; Pre = prevaccination.
a CIs are back-transformations of conﬁdence levels based on the Student t distribution for the mean logarithm of the concentrations.
b GMFRs were calculated after the infant series.
c GMFRs calculated after the second vaccination.
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Table 4
Percentage of subjects with a pneumococcal IgG antibody concentration ≥0.35 g/mL prevaccination and 1 month after the last PCV7 vaccination.
Serotype Age group, % (95% CI)a
121–<212 d 212 d–<12 mo  12–<24 mo  24–<72 mo
n = 85–88 n = 64–87 n = 100–115 n = 169–177
Pre 1 Month Pre 1 Month Pre 1 Month Pre 1 Month
4 0 (0, 4.1) 98.9 (93.8, 100) 0 (0, 4.2) 100 (95.8, 100) 2.6 (0.5, 7.4) 100 (96.8, 100) 11.0 (6.8, 16.7) 100 (97.9, 100)
6B  10.5 (4.9, 18.9) 98.9 (93.8, 100) 28.1 (17.6, 40.8) 100 (95.8, 100) 49.0 (38.9, 59.2) 99.1 (95.2, 100) 85.9 (79.9, 90.6) 100 (97.9, 100)
9V  12.5 (6.4, 21.3) 100 (95.9, 100) 13.1 (6.7, 22.2) 100 (95.8, 100) 29.2 (21.0, 38.5) 100 (96.8, 100) 72.9 (65.7, 79.3) 100 (97.9, 100)
14  29.5 (20.3, 40.2) 100 (95.9, 100) 4.6 (1.3, 11.4) 100 (95.8, 100) 9.6 (4.9, 16.5) 100 (96.8, 100) 49.7 (42.1, 57.3) 99.4 (96.9, 100)
18C  2.3 (0.3, 8.0) 98.9 (93.8, 100) 1.1 (0, 6.2) 98.9 (93.8, 100) 3.5 (1.0, 8.7) 100 (96.8, 100) 26.2 (19.8, 33.4) 100 (97.9, 100)
19F  13.6 (7.2, 22.6) 93.1 (85.6, 97.4) 14.1 (7.5, 23.4) 94.3 (87.1, 98.1) 22.6 (15.3, 31.3) 96.5 (91.3, 99.0) 71.6 (64.2, 78.3) 97.2 (93.5, 99.1)
23F  3.5 (0.7, 10.0) 97.7 (92.0, 99.7) 13.3 (6.6, 23.2) 98.9 (93.8, 100) 36.3 (27.0, 46.4) 99.1 (95.3, 100) 77.6 (70.7, 83.5) 99.4 (96.9, 100)
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Conﬂict of interest statementgG = immunoglobulin G; PCV7 = 7-valent pneumococcal conjugate vaccine; Pre = pr
a Exact 2-sided conﬁdence interval based on the observed proportion of subjects
n 8 subjects). The majority of AEs were mild (n = 8) or moderate
n = 4) in severity; all were considered to be related to PCV7. There
ere no protocol-related AEs.
SAEs were reported in 2 subjects. Enteritis was reported in 1 sub-
ect aged 121 to <212 days after the ﬁrst dose of PCV7; the event
esolved after 7 days. Three SAEs were reported in 1 subject in the
2 to <24 months age group during the 12-month follow-up: gas-
roenteritis (shigella), respiratory failure, and circulatory collapse;
his subject died. None of these SAEs were considered related to
CV7. The only study withdrawal occurred in the subject who  died.
. Discussion
PCV7 catch-up regimens in China in vaccine-naive older infants
nd young children resulted in a robust immune response to all vac-
ine serotypes. In all age groups, serotype-speciﬁc antibody levels
ncreased 1 month following the last vaccination relative to pre-
accination levels, with more than 90% of subjects achieving an
gG ≥ 0.35 g/mL for all 7 serotypes. Antibody concentrations were
enerally higher in the oldest children 1 month after the last vac-
ination and at the 12-month follow-up. A more robust immune
esponse in older children is consistent with a better-developed
mmune system compared with younger children, the potential of
rior exposure, and the development of immunologic memory. Pre-
accination IgG antibodies were generally higher in the older age
roup and may  be suggestive of prior exposure to S. pneumoniae. In
ddition, the youngest infants (121 to <212 days) had a relatively
igh level of IgG to serotype 14 compared with infants aged 212
ays to <24 months, suggesting a possible contribution of mater-
al antibodies (passive immunity) and potential exposure for this
erotype.
In this study, older children receiving a 1- or 2-dose PCV7 catch-
p regimen achieved immune responses comparable to those in
ounger infants receiving a 3- or 4-dose catch-up regimen. A trend
or robust immune responses in older children after initial PCV7
mmunization is supported by a study conducted in Israeli and
edouin toddlers receiving 1 or 2 doses of PCV7 in a catch-up reg-
men. In that study, serotype-speciﬁc immune responses after 2
oses of PCV7 administered to vaccine-naive toddlers between 12
nd 18 months of age were similar to or higher than the immune
esponse in younger children receiving a standard dosing regimen
16].
In this study, increased levels of circulating IgG persisted 12
onths after the last vaccination in all age groups. AlthoughgG levels had waned compared with levels assessed at 1 month
ostvaccination, they remained higher than prevaccination levels.
verall, the majority of subjects retained IgG GMCs ≥ 0.35 g/mL
or each of the 7 serotypes 12 months postvaccination.ination.
Although this study did not examine responses beyond 12
months postvaccination, evidence from a recent Finnish study sug-
gests extended durability beyond 1 year [17]. Speciﬁcally, 5 years
after Finnish infants received a 4-dose PCV7 series at 2, 4, 6, and
12 months of age, the proportion of children with IgG ≥ 0.35 g/mL
remained signiﬁcantly higher (P < 0.001) in vaccinated infants com-
pared with control infants. As with most vaccine studies that assess
durability, circulating antibody was  the analysis endpoint, which
does not consider the contribution of latent, long-lived memory
B cells to long-term protective immunity. In this current study,
the highest antibody levels at 12 months postvaccination were
found in older children who had received 1 dose of PCV7, sug-
gesting that age at vaccination may  be an important contributor to
durability.
PCV7 was  well tolerated in all study subjects. The majority of
AEs were due to fever; these were mild to moderate in severity,
self-limited, and considered related to PCV7. Two  subjects reported
SAEs, neither of which were considered related to the vaccine.
Other than 1 death, which was deemed unrelated to treatment,
there were no study withdrawals; no protocol violations were
reported.
Certain strengths and limitations should be considered when
evaluating the study results. To date, this is the only catch-up
study completed in Asia with a 12-month extension for antibody
persistence, and it thereby provides valuable information on pneu-
mococcal antibody durability in Asian children. Four different age
groups were examined according to recommended dosing sched-
ules, providing a real-world context for evaluation. In conclusion,
PCV7 catch-up vaccinations given to older infants and young chil-
dren naive to pneumococcal vaccines in China resulted in a robust
immune response to all serotypes; this response persisted after 1
year. PCV7 was well tolerated in infants and children.
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